Aignostics is a spin-off from Charité – Universitätsmedizin Berlin and Berlin Institute of Health (BIH), developing novel digital pathology solutions with “Explainable AI” for pharmaceutical research and diagnostics. It announced the closing of an oversubscribed €14m Series A financing round. Wellington Partners led the round, joined by existing investors Boehringer Ingelheim Venture Fund (BIVF), VC Fonds Technologie of IBB Ventures and High-Tech Gründerfonds (HTGF). The CARMA Fund that was recently co-founded by Ascenion has also participated as a new investor.
Aignostics’ technology not only enables to analyse tissue samples using AI, but also to display the analysis process graphically and thus show the morphological differences between different tissue samples. This makes it possible to explain why certain tissue samples respond positively or negatively to a therapy. Aignostics thus makes an essential contribution to improve understanding of disease biology, mode of action, or novel biomarkers and drug response characteristics.
Ascenion holds equity in Aignostics. Revenues Ascenion may receive from a potential future exit will largely be distributed to the LifeScience Foundation, which in turn makes them available to its endowing institutes as research grants, including the Charité.
Further information: